Applied Proteomics said this week that it has closed a $28 million Series C financing round.
In March 2010, Austin, Texas-based diagnostics firm Vermillion launched sales of its OVA1 ovarian cancer test.
NEW YORK (GenomeWeb News) – Epic Sciences today announced it has completed its Series B financing round raising $13 million.
Protein biomarker diagnostics firm Astute Medical this week said it had completed a Series C financing round that raised $40.4 million.
By Adam Bonislawski
Applied Proteomics announced this week that it has appointed Peter Klemm as CEO and James Blair to its board of directors.
The company said it will use the money, which is an extension of a $26.5 million Series B round completed in May 2010, to advance and expand research, development, and validation of protein biomarker-based laboratory tests.
MBI plans to use the series B venture funding to develop its Apollo sample prep technologies.
The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.
In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.
The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.
In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.